About Medicago
Medicago is a company based in Quebec City (Canada) founded in 1999 was acquired by Mitsubishi Tanabe Pharma in July 2013. Medicago has raised $49.75 million across 3 funding rounds from investors including Philip Morris International, Mitsubishi Tanabe Pharma and Yorkville Advisors. Medicago operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Serum Institute of India, Vaxcyte and Generate Biomedicines, among others.
- Headquarter Quebec City, Canada
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$49.75 M (USD)
in 3 rounds
-
Latest Funding Round
$24.23 M (USD), Series B
Sep 27, 2011
-
Investors
Philip Morris International
& 2 more
-
Employee Count
Not available
-
Acquired by
Mitsubishi Tanabe Pharma
(Jul 12, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Medicago
Medicago has successfully raised a total of $49.75M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $24.23 million completed in September 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Medicago
Medicago has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Philip Morris International, Mitsubishi Tanabe Pharma and Yorkville Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Offers flexible capital to micro-cap and small-cap firms for growth.
|
Locked | Locked | Locked | |
|
Multi-category tobacco products, including cigarettes and heated options, are manufactured.
|
Locked | Locked | Locked | |
|
Innovative therapies and drugs are developed by the pharmaceutical company.
|
Locked | Locked | Locked |
Investor details for Medicago
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Medicago
Investment portfolio details for Medicago
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Medicago
Detailed financials for Medicago
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Medicago Comparisons
Peer comparison for Medicago
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Medicago
Medicago operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Serum Institute of India, Vaxcyte and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
Detailed competitors of Medicago
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Medicago
Complete news archive for Medicago
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medicago
Medicago was founded in 1999 and raised its 1st funding round 9 years after it was founded.
Medicago is headquartered in Quebec City, Canada. It is registered at Quebec City, Quebec, Canada.
Toshifumi Tada is the current CEO of Medicago.
Medicago is a funded company, having raised a total of $49.75M across 3 funding rounds to date.
Founded in 1999 and based in Quebec City, Canada, Medicago operates in the biotechnology sector, focusing on influenza vaccine development. Proprietary technologies, including plant-based Proficia and Virus-Like Particles, are utilized to create candidates such as H5N1 pandemic, H1N1 for Influenza ACalifornia0409, and seasonal influenza vaccines, which are in phase 3 clinical trials. Collaborations with Viridis S.A., Genopole Bio park, and Philip Morris International support manufacturing and protein production efforts.
Medicago's top competitors include Moderna, Adaptive Biotechnologies and Vaxcyte.
Medicago has 3 investors. Key investors include Philip Morris International, Mitsubishi Tanabe Pharma, and Yorkville Advisors.